Tollys
  • About Us
    • Company
    • Board of Directors
    • Management
    • Scientific Advisory Board
  • Science
    • Immuno-oncology
    • TLR3 Science
    • Publications
  • Product
    • TL-532
    • Intellectual property
  • Pipeline
    • Bladder Cancer
    • TLR3+ Cancers
  • News
  • Careers
  • Contact
Select Page

Login Customizer

This page is used for Login Customizer plugin. It will not be visible to your readers. Do not delete it.

Recent Posts

  • Tollys appoints Philippe Goupit as chairman of the board
  • Tollys extends its executive management team with appointment of Bettina Werle as CSO
  • Tollys receives over €1.5 million deep tech financing from Bpifrance
  • Tollys closes pre-Series A financing of €2.3 million
  • Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma

Recent Comments

    Archives

    • February 2021
    • October 2020
    • July 2020
    • May 2020
    • December 2019
    • November 2019
    • August 2018
    • June 2016
    • January 2015
    • September 2012
    • March 2011
    • December 2007
    • August 2007
    • April 2006
    • September 1991
    • July 1980

    Categories

    • News
    • Publications

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Design by Small Stories ©2019